Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

Figure 2

Interleukin (IL)-6 (a) and serum amyloid A (SAA) levels (b) over the course of the study by treatment group.a Data are presented as median (interquartile range) *1 week after the start of part 1. Upper limit of normal range for SAA was 10 mg/L.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us